Sie sind auf Seite 1von 3

38

DAFTAR PUSTAKA

1. Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, et al.


Bortezomib with thalidomid plus dexamethasone compared with
thalidomide plus dexamethasone as induction therapy before, and
consolidation therapy after, double autologous stem-cell transplantation in
newly-diagnosed multiple myeloma: arandomised phase 3 study. Lancet
2010;376:2075-85.
2. Palumbo A, Bringhen S, Rossi D,Cavalli M, Larocca A, Ria R, et. al.
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance
with bortezomib-thalidomide compared with bortezomib-melphalan-
prednisone for initial treatment of multiple myeloma: a randomized
controlled trial. J Clin Oncol 2010;28:5101-9.
3. Mateos M-V, Oriol A, Lopez JM, Teruel AI, Guia ALDL, Lopez J, et al.
GEM 2005 trial update comparing VMP/VTP as induction in elderly
multiple myeloma patients: do we still need alkylators? Blood
2014;124912):1887-93.
4. Hulin C, Facon T, Rodon P, Pegourie B, Benboubker L, Doyen C, et al.
Efficacy of melphalan and prednisone plus thalidomide in patients older
than 75 years with newly diagnosed multiple myeloma : IFM 01/01 trial. J
Clin Oncol. 2009;22:3664-70.
5. Fayers PM, Palumbo A, Hulin C, Waage A, Wijermans P, Beksa M, et al.
Thalidomide for previously untreated elderly patients with multiple
myeloma: meta-analysis of 1685 individual patient data from 6
randomized clinical trials. Blood. 2011;118:1239-47.
6. Ludwig H, Hajek R, Tthov E et al. Thalidomide-dexamethasone
compared with melphalan-prednisolone in elderly patients with multiple
myeloma. Blood 2009;113:34353442.
7. Kyle RA, Rajkumar SV. Drug therapy multiple myeloma. N Engl J Med.
2004;351:1860-73.
8. Genadieva-Stavric S, Cavallo F, Palumbo A. New approaches to
management of multiple myeloma. Curr Treat Opt Oncol 2014;15(2):157-
70.
9. Cavo M, Rajkumar SV, Palumbo A, Moraeu P, Orlowski R, Blade J, et al.
International Myeloma Working Group consensus approach to the
39

treatment of multiple myeloma patients who are candidates for autologous


stem-cell transplantation. Blood 2011;11(23):6063-73.
10. Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niezvizky R,
Morgan G, et al. International Myeloma Working Group consensus
statement for the management, treatment, and supportive care for myeloma
patients who are not eligible for standard autologous stem-cell
transplantation. J Clin Oncol. 2014;32:1-17.

11. Rhee FV, Anaissie E, Angtuaco E, Bartel T, Epstein J, Nair B, et al.


Myeloma. In: Kaushansky K, Lichtman MA, Beuler E, Kipps TJ,
Seligsohn U, Prchal JT, editors. Williams Hematology. 8th ed. New York:
Mc Graw Hill; 2010.p.1645-81.
12. Tadjoedin H, Reksodiputro AH, Toruan T, Kosasih AA, Supandiman I,
Sumantri R, et al. Multiple myeloma in Indonesia. Indonesian J Cancer.
2011;2(5):76-81.
13. Saraf S, Patel P, Rondelli D. Epidemiology, biology, and outcome in
multiple myeloma patients in different geographical areas of the world. J
Adv Intern Med 2012;01:20-32.
14. Al-Farsi K. Multiple myeloma : An update. Oman Med J. 2013;1(28):3-11.
15. Kim K, Lee JH, Kim JS, Min CK, Yoon SS, Shimizu K, et al. Clinical
profiles of multiple myeloma in Asia-An Asian Myeloma Network study.
Am J Hematol. 2014;89:751-6.
16. Sinuraya ES. Registrasi Kanker Rumah Sakit Kanker Dharmais tahun
1993-2010.
17. Alexander DD, Mink PJ, Adami HO, Cole P, Mandel JS, Oken MM, et al.
Multiple myeloma: a review of the epidemiologic literature. Int J Cancer.
2007;120 Suppl 12:40-61.
18. Khan MM, Mori Mitsuru, Sakauchi Fumio, Matsuo K, Ozasa K,
Tamakoshi A. Risk factor for multiple myeloma: Evidence from the Japan
Collaborative Cohort (JACC) Study. 2006. Asian Pac J Cancer Prev.
2006;7:575-81
19. Palumbo A, Anderson K. Multiple Myeloma. N Engl J Med
2011;364:1046-60.
40

20. Tan D, Chng WJ, Chou T, Nawarawong SY, Hwang SY, Chim CS, et al.
Management of multiple myeloma in Asia: resource-startified guidelines.
Lancet 2013;14:571-9.
21. Bringhen S, Mateos MV, Zweegman S, Larocca A, Falcone AP, Oriol A, et
al. Age and organ damage correlate with poor survival in myeloma
patients: Meta-analysis of 1435 individual patient data from 4 randomized
trials. Haematologica 2013;98:980-7.
22. Chanan-Khan AA, Giralt S. Importance of achieving a complete response
in multiple myeloma, and the impact of novel agents. J Clin Oncol.
2010;15(28):2612-24.
23. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi
FK, et al. Improved survival in multiple myeloma and the impact of novel
therapies. Blood. 2008;5(111):2516-20.
24. Gay F, Larocca A, Wijermans P, Cavallo F, Rossi D, Schaafsma R, et al.
Complete response correlates with long-term progression-free and overall
survival in elderly myeloma treated with novel agents: analysis of 1175
patients. Blood. 2011;117:3025-31.
25. Moreau P, Attal M, Facon T. Frontline therapy of multiple myeloma.
Blood. 2015;20:3076-84.
26. Durie BGM, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K,
et al. International uniform response criteria for multiple myeloma.
Leukemia. 2006;20:1467-73.
27. Chang X, Zhu Y, Shi C, Stewart AK. Mechanism of immunomodulatory
drugs action in the treatment of multiple myeloma. Acta Biochim Biophys
Sin. 2014;46(3):240-7.